UNSPSC 51332006: Paliperidone palmitate

This classification denotes a serotonin antagonist and dopamine antagonist and antipsychotic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R8P8USM8FR. European Medicines Agency schedules Paliperidone palmitate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB31687. Paliperidone palmitate generally arises in the molecular formula C39H57FN4O4. The term 'paliperidone palmitate' is a United States Adopted Name designation.

Most nations, for tariff and trade purposes, schedule paliperidone palmitate under HS 29349990 and SITC 51579. As of Q4 2014, PALIPERIDONE PALMITATE remains US FDA's Preferred Term for this commodity. Paliperidone palmitate bears US NLM identifiers UMLS ID C2719626 and NCI Concept Code C83917. SMILES: CCCCCCCCCCCCCCCC(=O)OC1CCCN2C1NC(C(C2=O)CCN3CCC(CC3)C4C5CCC(CC5ON4)F)C.

UNSPSC 51332006 Paliperidone palmitate, a Commodity code, nominally designates a specific antipsychotic pharmaceutical active ingredient, but recent state and local opportunities tagged under this code show little direct purchasing activity for the named drug; instead, they reflect broader pharmaceutical procurement spanning naloxone, generic multi-source drugs, over-the-counter products, and direct-to-manufacturer prescription fulfillment programs. State and local agencies—including county health departments, state health and human services commissions, and multistate cooperative purchasing alliances—use this code range to organize acquisitions of pharmaceutical products and related supply-chain services. The scope encompasses unit purchases of finished pharmaceutical products for community health initiatives, cooperative multi-state contracts for generic and OTC drugs distributed through authorized wholesalers, and emerging direct-to-manufacturer prescription programs designed to bypass traditional pharmacy benefit managers and group purchasing organizations.

Activity appears across multiple states, with recent solicitations from Florida (Seminole County), Texas (HHS Commission), and Minnesota (MMCAP, serving multiple states including Oregon). Representative opportunities include Seminole County's IFB 60459723LAS (posted June 30, 2026, due July 26, 2026) for annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries; the Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026) seeking vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program; and MMCAP's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) to establish multi-award contracts for generic pharmaceuticals and OTC products distributed through AmerisourceBergen (Cencora), Cardinal Health, and Morris & Dickson, with awards effective July 1, 2026. The MMCAP procurement emphasizes cGMP compliance, Drug Supply Chain Security Act certification, and EDI capability, with evaluation weighted 75 percent on price competitiveness and 25 percent on administrative compliance and data standards.